
About Rekvina Laboratories Limited
Data last updated:
Rekvina Laboratories Limited is a public limited company based in Vadodara, Gujarat, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 01 November 1988 and has been in existence for over 38 years.
The company is registered with the Registrar of Companies (ROC), Ahmedabad, under CIN L24231GJ1988PLC011458. The company has 1 GST registration on record, which is no longer active. It is a listed company as per MCA records. Its shares are listed on BSE: 526075.
The company has an authorised share capital of ₹3.5 Cr and a paid-up capital of ₹3.01 Cr. It was formerly known as Rekvina Laboratories Private Limited. It is led by directors including Amit Mukesh Shah (Managing Director) and Ila Rajendra Pathak.
Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Vadodara, Gujarat.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹1.27 Cr. For the same year it recorded a net loss of ₹25 Lakh (net margin -19.7%) and EBITDA of -₹25 Lakh (EBITDA margin -19.7%). Total assets are valued at ₹24 Lakh (up 366.7% YoY).
The company is associated with 1 brand: Rekvina Laboratories. As per MCA filings, the company has open charges of ₹8.04 Cr on record. Court records list 8 cases involving the company, including 5 filed by the company and 3 filed against it. The company has 81 deals on record (81 market trades); the latest was in June 2018.
The current compliance status is marked as active non-compliant by the Registrar of Companies. For more details, the company can be reached via its website rekvinalaboratories.com.
Company details
CIN history
Rekvina Laboratories has one previous CIN (Corporate Identification Number): U24231GJ1988PLC011458. The current CIN is L24231GJ1988PLC011458, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231GJ1988PLC011458 | Current |
| U24231GJ1988PLC011458 | Previous |
Contact details
Rekvina Laboratories Limited's registered office is in Vadodara, Gujarat. Its website is rekvinalaboratories.com. Its e-mail address is in the company report.
- Email
- Website
- Registered Address36 Sampatrao Colony, Next To Royal Hotel, Vadodara, Gujarat, India – 390007
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Rekvina Laboratories Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Rekvina Laboratories operates one associated brand: Rekvina Laboratories. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Medicines for gynecological disorders and surgical therapeutics are developed. | rekvinalaboratories.com |
Financials of Rekvina Laboratories Limited
FY 2025-26 filings availableRekvina Laboratories Limited reported revenue of ₹1.27 Cr for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 1.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | (0.25) | (0.13) | (0.02) | 0.00 | (0.08) | (0.07) | (0.15) |
| EBITDA margin | -19.7% | - | - | - | - | - | - |
| Profit before tax | (0.25) | (0.13) | (0.02) | 0.00 | (0.08) | (0.07) | 0.00 |
| Net profit | (0.25) | (0.13) | (0.02) | 0.00 | (0.08) | (0.07) | 0.00 |
| Net profit margin | -19.7% | - | - | - | - | - | - |
| EPS (₹) | (0.42) | (0.23) | (0.03) | 0.00 | (0.13) | (0.11) | 0.00 |
| Balance sheet | |||||||
| Total assets | 0.24 | (0.09) | (0.16) | 0.09 | 0.01 | 0.09 | 0.16 |
| Net worth | (1.23) | (0.34) | (0.20) | 0.01 | 0.01 | 0.09 | 0.15 |
| Total debt | 1.47 | 0.25 | 0.04 | 0.08 | 0.00 | 0.00 | 0.00 |
| Cash & bank | 0.02 | 0.03 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 |
| Net working capital | 0.26 | (0.08) | (0.16) | (0.10) | (0.18) | (0.14) | (0.08) |
| Cash flow | |||||||
| Cash from operations | (0.59) | (0.19) | (0.01) | 0.01 | (0.04) | (0.01) | - |
| Cash from investing | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | - |
| Cash from financing | 0.58 | 0.21 | 0.01 | 0.00 | 0.00 | 0.00 | - |
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.59 | 0.67 | 0.72 | 0.35 | 0.20 | 0.00 | 0.00 | 0.00 |
| Revenue growth (YoY) | +195.0% | - | - | - | - | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.65 | 0.79 | 0.78 | 0.47 | 0.23 | 0.04 | 0.04 | 0.02 |
| EBITDA | (0.06) | (0.12) | (0.06) | (0.12) | (0.03) | (0.04) | (0.04) | (0.02) |
| EBITDA margin | -10.2% | -17.9% | -8.3% | -34.3% | -15.0% | - | - | - |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.06) | (0.12) | (0.06) | (0.12) | (0.03) | (0.04) | (0.04) | (0.02) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Financial Statements
| Particulars | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.59 | 0.67 | 0.72 | 0.35 | 0.20 | 0.00 | 0.00 | 0.00 |
| Revenue growth (YoY) | +195.0% | - | - | - | - | - | - | - |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total expenses | 0.65 | 0.79 | 0.78 | 0.47 | 0.23 | 0.04 | 0.04 | 0.02 |
| EBITDA | (0.06) | (0.12) | (0.06) | (0.12) | (0.03) | (0.04) | (0.04) | (0.02) |
| EBITDA margin | -10.2% | -17.9% | -8.3% | -34.3% | -15.0% | - | - | - |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.06) | (0.12) | (0.06) | (0.12) | (0.03) | (0.04) | (0.04) | (0.02) |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.27 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.15 |
| Total expenses | 1.52 | 0.13 | 0.02 | 0.00 | 0.08 | 0.07 | 0.15 |
| Employee cost | 0.23 | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
| EBITDA | (0.25) | (0.13) | (0.02) | 0.00 | (0.08) | (0.07) | (0.15) |
| EBITDA margin | -19.7% | - | - | - | - | - | - |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.25) | (0.13) | (0.02) | 0.00 | (0.08) | (0.07) | 0.00 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (0.25) | (0.13) | (0.02) | 0.00 | (0.08) | (0.07) | 0.00 |
| Net profit margin | -19.7% | - | - | - | - | - | - |
| EPS (₹) | (0.42) | (0.23) | (0.03) | 0.00 | (0.13) | (0.11) | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 | 3.01 |
| Reserves & surplus | (4.24) | (3.35) | (3.21) | (3.00) | (3.00) | (2.92) | (2.86) |
| Shareholders' funds (net worth) | (1.23) | (0.34) | (0.20) | 0.01 | 0.01 | 0.09 | 0.15 |
| Secured loans | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | 1.47 | 0.25 | 0.04 | 0.08 | 0.00 | 0.00 | 0.00 |
| Total debt | 1.47 | 0.25 | 0.04 | 0.08 | 0.00 | 0.00 | 0.00 |
| Total liabilities | 0.24 | (0.09) | (0.16) | 0.09 | 0.01 | 0.09 | 0.16 |
| Assets | |||||||
| Gross block | 0.00 | 0.00 | 0.00 | 0.51 | 0.51 | 0.51 | 0.39 |
| Net block | 0.00 | 0.00 | 0.00 | 0.14 | 0.14 | 0.14 | 0.14 |
| Capital work in progress | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.05 | 0.05 | 0.05 | 0.05 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | 0.60 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank balances | 0.02 | 0.03 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 |
| Loans & advances | 0.58 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.03 |
| Total current assets | 1.20 | 0.04 | 0.01 | 0.01 | 0.00 | 0.01 | 0.04 |
| Total current liabilities | 0.94 | 0.12 | 0.17 | 0.11 | 0.18 | 0.15 | 0.12 |
| Net working capital | 0.26 | (0.08) | (0.16) | (0.10) | (0.18) | (0.14) | (0.08) |
| Total assets | 0.24 | (0.09) | (0.16) | 0.09 | 0.01 | 0.09 | 0.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.03 | 0.01 | 0.01 | 0.00 | 0.00 | 0.01 | - |
| Net cash from operating activities | (0.59) | (0.19) | (0.01) | 0.01 | (0.04) | (0.01) | - |
| Net cash from investing activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | - |
| Net cash from financing activities | 0.58 | 0.21 | 0.01 | 0.00 | 0.00 | 0.00 | - |
| Net change in cash | (0.01) | 0.02 | 0.00 | 0.01 | 0.00 | (0.01) | - |
| Closing cash | 0.02 | 0.03 | 0.01 | 0.01 | 0.00 | 0.00 | - |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| EBITDA growth | -92.3% | -550.0% | - | +100.0% | -14.3% | +53.3% | - |
| PBT growth | -92.3% | -550.0% | +9997.0% | +9997.0% | -14.3% | +9997.0% | +9997.0% |
| Net income growth | -92.3% | -550.0% | - | +100.0% | -14.3% | - | - |
| Revenue CAGR (3Y) | - | - | - | - | - | - | -100.0% |
| EBITDA CAGR (3Y) | - | +17.6% | -34.1% | -100.0% | -7.2% | +20.5% | +35.7% |
| Profitability & leverage | |||||||
| Net income margin | -19.7% | - | - | - | - | - | - |
| Return on capital employed | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - |
| Return on net worth | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | - |
| Debt / equity | 0.00 | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | - |
| Long-term debt / equity | 0.00 | 0.00 | 0.00 | -0.07 | 0.00 | 0.00 | - |
| Interest cover | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Debtors turnover | 4.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| EPS (₹) | (0.42) | (0.23) | (0.03) | 0.00 | (0.13) | (0.11) | 0.00 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | (2.04) | (0.55) | (0.32) | 0.02 | 0.02 | 0.15 | 0.26 |
To see the full year-wise statements and ratios of Rekvina Laboratories Limited, buy the company report.
Board of directors of Rekvina Laboratories Limited
Rekvina Laboratories has 5 current directors and 8 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Amit Mukesh Shah Also directs: Radiant Parenterals Limited, Rekvina Pharmaceuticals (India) Private Limited, Pansoft Data Solutions Private Limited and 2 more | Managing Director | 01 Aug 2000 | 26 Years 3 Months | Current |
| Jay Chintan Patel Also directs: Duchas Technologies Private Limited | Additional Director | 29 Jan 2026 | 0 Years 9 Months | Current |
| Ila Rajendra Pathak Also directs: Radiant Parenterals Limited | Director | 02 Sep 2024 | 2 Years 2 Months | Current |
| Prateek Jain Also directs: Jayam & Associates LLP | Additional Director | 06 Oct 2025 | 1 Years 1 Months | Current |
| Surbhit Mukesh Shah Also directs: Radiant Parenterals Limited, Rekvina Pharmaceuticals (India) Private Limited, Varshaben Mukeshbhai Shah Foundation and 1 more | Director | 27 Sep 2024 | 2 Years 1 Months | Current |
Auditor
Rekvina Laboratories Limited is audited by JIGAR ADHYARU & CO for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| JIGAR ADHYARU & CO | FY 2023 | 142223W |
Shareholding
Shareholding for the quarter ended Jun 2026: promoters hold 41.30%, foreign institutional investors hold 0.00%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 58.70%.
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | |
|---|---|---|---|---|
| Promoters | 41.30% | 41.30% | 41.30% | 41.30% |
| Public | 58.70% | 58.70% | 58.70% | 58.70% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 30 Dec 2203 | 90100140 | Bank of Baroda | ₹5 Lakh | Open | |
| 13 Jul 1999 | 90099030 | Bank of Baroda | ₹1.9 Cr | Open | |
| 24 Sep 1997 | 90096485 | Bank of Baroda | ₹1.9 Cr | Open | |
| 13 Jul 1994 | 90097921 | Bank of Baroda | ₹1.9 Cr | Open | |
| 10 Dec 1993 | 90097799 | Bank of Baroda | ₹53 Lakh | Open |
To see the full charge records of Rekvina Laboratories Limited, buy the company report.
Total charge records: 10 View all charges
Deals & funding
Rekvina Laboratories Limited has 81 deals on record (81 market trades); the latest was in June 2018.
Deals on record (5 of 81)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2018 | Market trade | ₹7.3 Lakh | Buyer: 2 individuals Seller: Arcadia Share and Stock Brokers Private Limited |
| Jun 2018 | Market trade | ₹7.9 Lakh | Buyer: 2 individuals Seller: Arcadia Share and Stock Brokers Private Limited |
| Apr 2017 | Market trade | ₹9.6 Lakh | Buyer: 3 individuals Seller: GN Credits Private Limited , 2 individuals |
| Oct 2016 | Market trade | ₹19.1 Lakh | Buyer: Ashamakam Mercantile Private Limited , 3 individuals Seller: 3 individuals |
| Sep 2016 | Market trade | ₹2.8 Lakh | Buyer: Ashamakam Mercantile Private Limited Seller: an individual |
To see the full deal history of Rekvina Laboratories Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Rekvina Laboratories Limited has 8 court cases on record: 5 filed by Rekvina Laboratories, 3 filed against it. All cases are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 6 | 1 | 0 |
| District courts | 2 | 2 | 0 |
Cases on record (3 of 8)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Panchmahal at Godhra, Gujarat | Interim or miscellaneous application | Filed against the company by an individual | Disposed |
| High Court, GUJARAT | Court case (TAXAP) | Filed by the company against Income Tax Officer Ward 4( | Disposed |
| High Court, GUJARAT | Court case (TAXAP) | Filed against the company by Income Tax Officer 4( and 1 other | Disposed |
To see the full case history of Rekvina Laboratories Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Rekvina Laboratories Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Rekvina Laboratories has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Rekvina Laboratories Limited, buy the company report.
Recent activity
Rekvina Laboratories Limited has 15 board changes on record since 1997: 9 appointments and 6 cessations. The latest: Jay Chintan Patel was appointed as Additional Director on 29 Jan 2026.
19 earlier events are in the company report.
Frequently asked questions
Rekvina Laboratories is an active public limited company based in Vadodara, Gujarat, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 01 November 1988 (38+ years old) and is registered under CIN L24231GJ1988PLC011458. Listed on BSE: 526075.
Rekvina Laboratories reported revenue of ₹1.27 Cr for FY 2025-26 based on standalone financials.
Rekvina Laboratories has 5 current directors:
- Amit Mukesh Shah - Managing Director
- Jay Chintan Patel - Additional Director
- Ila Rajendra Pathak - Director
- Prateek Jain - Additional Director
- Surbhit Mukesh Shah - Director
The latest financial statements of Rekvina Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 26 September 2025. Year-wise statements from 2015 are in the company report.
No. Rekvina Laboratories has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Rekvina Laboratories is L24231GJ1988PLC011458. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Rekvina Laboratories is a listed company as per MCA records. Its shares are listed on BSE (code: 526075).
Rekvina Laboratories has 8 court cases on record: 5 filed by the company and 3 filed against it. Most are in the high courts.
Rekvina Laboratories was incorporated on 01 November 1988, making it 38+ years old. It is registered with the Registrar of Companies, Ahmedabad.
Rekvina Laboratories has 81 deals on record (81 market trades); the latest was in June 2018.

